Does NMN really reduce blood pressure? Clinical trials now confirm that nicotinamide mononucleotide (NMN) can significantly lower blood pressure in adults with hypertension by restoring NAD+ levels and improving vascular function.

NMN is best known as a longevity molecule, but emerging evidence suggests it may also offer therapeutic benefits for people dealing with cardiovascular issues like high blood pressure.

Let’s take a look at what science has to say. 

What Is NMN And Why Might It Affect Blood Pressure?

NMN is a molecule that increases NAD+ levels in your cells, which improves blood vessel function, energy metabolism, and cellular repair—making it potentially useful for reducing high blood pressure.

Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme critical for energy production and maintaining cellular health. 

As we age, NAD+ levels naturally decline. Fortunately, studies have shown that NMN supplementation improves NAD+ levels in aging individuals.

Can NMN Reduce Systolic Blood Pressure In People With Hypertension?

Yes. In a clinical trial, 800 mg/day of NMN for six weeks significantly lowered systolic blood pressure in hypertensive adults compared to lifestyle changes alone.

A 2023 randomized controlled trial from Sun Yat-sen University investigated the effects of NMN on 19 adults with mild hypertension. Participants were split into two groups. One group received 800 mg of oral NMN daily for six weeks along with lifestyle modifications (low-salt diet and regular exercise). The other group (control group) followed lifestyle changes only.

Compared to the control group, the NMN group experienced a significant reduction in systolic blood pressure. Systolic blood pressure is the upper number in a blood pressure reading. 

Importantly, NMN also increased blood NAD+ levels by approximately 43%. The endothelial function of the NMN group was also improved. Endothelial function refers to the various processes performed by your blood vessels. Usually, when there’s endothelial dysfunction, it may cause hypertension. 

Therefore, an improvement in endothelial function in response to NMN supplementation is a very promising result. This suggests that there may be a strong mechanistic link between NAD+ restoration and blood pressure reduction. 

Does NMN Lower Diastolic Blood Pressure Too?

Yes, clinical evidence shows that NMN significantly lowers diastolic blood pressure in overweight adults.

In a randomized, human trial conducted by Harvard researchers, overweight and obese adults were given a daily oral dose of 2,000 mg of NMN for 28 days.

At the end of the study, people who received NMN had a significantly lower diastolic blood pressure compared to the people who received a placebo. Diastolic blood pressure (DBP) measures the pressure in your arteries when your heart rests between beats. 

Elevated DBP is associated with greater vascular resistance and increased cardiovascular risk. By reducing DBP, NMN may help ease the strain on your blood vessels which could potentially lower the risk of heart disease and stroke over time.

Importantly, the study also confirmed that NMN was well tolerated. No adverse effects were reported across the 28-day period, supporting its short-term safety profile at higher doses.

The trial also found that the NMN group had reductions in body weight and LDL cholesterol. This suggests that NMN might play a broader role in the metabolic health of an individual.

What Happens to NAD+ In Hypertension?

Hypertension is a chronic illness that is linked to inflammation. Due to inflammation, the levels of CD38 enzyme rise in blood vessels. This enzyme degrades NAD+. 

Here’s how it works: 

1. Inflammation triggers macrophages to move into blood vessels. Macrophages are your body’s soldiers. 

2. In the blood vessels, macrophages produce IL-1β. This is a molecule that causes an increase in the CD38 levels. 

3. The higher CD38 levels lead to more NAD+ degradation. 

Can NMN Raise Blood Pressure Instead?

No. Human trials show NMN does not raise blood pressure, even at high doses. It is well tolerated and considered safe.

In human studies, NMN did NOT increase blood pressure. Even at high doses (2,000 mg/day), participants experienced no rise in either systolic or diastolic readings.

That said, no long-term trials yet exist to assess the effects over several months or years—especially in people on blood pressure medications.

If you take antihypertensive drugs, consult your physician before adding NMN to your regimen, as it may enhance or repress the effects of medications.

Who Might Benefit Most From NMN For Blood Pressure?

Adults with mild hypertension, low NAD+ levels, or age-related vascular decline may benefit most from NMN supplementation.

Ideal candidates include:

• Adults with early-stage hypertension not yet on medication.
  

• Individuals with low energy. 

While NMN is not a replacement for antihypertensive drugs, it may complement lifestyle changes and offer preventive support.

What Is The Best Dose Of NMN For Blood Pressure Support?

Studies suggest 250–800 mg/day is effective and safe for supporting blood pressure, with 800 mg showing measurable reductions in hypertensive adults. However, you may need up to 2,000 mg/day to cause a significant decrease in diastolic blood pressure. 

• 800 mg/day: Lowers systolic pressure in patients with hypertension, as demonstrated by the study mentioned above.
  

• 2,000 mg/day: Lowers diastolic blood pressure in obese or overweight participants. This was the dose used by the study coming out of Harvard. It is effective but expensive and not widely adopted.

Final Thoughts: Does NMN Reduce Blood Pressure?

Clinical studies show NMN lowers both systolic and diastolic blood pressure. It also restores NAD+ levels and seems to improve vascular function. This makes it a promising natural tool for managing hypertension.

For adults with high blood pressure or declining vascular health, NMN offers a science-backed strategy to improve endothelial function, reduce arterial stiffness, and restore balance to the aging cardiovascular system.

If you are serious about supporting your blood pressure and overall heart health, NMN may be worth considering. However, it’s important to get the purest NMN available because impure formulations may not have therapeutic efficacy. 

Shop Ultra Pure NMN™ from HealthspanX!

References

• Yamane, T., Imai, M., Bamba, T., & Uchiyama, S. (2023). Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects. Clinical nutrition ESPEN, 56, 83–86. https://doi.org/10.1016/j.clnesp.2023.04.031
  
• Qiu, Y., Xu, S., Chen, X., Wu, X., Zhou, Z., Zhang, J., Tu, Q., Dong, B., Liu, Z., He, J., Zhang, X., Liu, S., Su, C., Huang, H., Xia, W., & Tao, J. (2023). NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. Signal transduction and targeted therapy, 8(1), 353. https://doi.org/10.1038/s41392-023-01577-3
  
• Gallo, G., Volpe, M., & Savoia, C. (2022). Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Frontiers in medicine, 8, 798958. https://doi.org/10.3389/fmed.2021.798958
  
• Pencina, K. M., Valderrabano, R., Wipper, B., Orkaby, A. R., Reid, K. F., Storer, T., Lin, A. P., Merugumala, S., Wilson, L., Latham, N., Ghattas-Puylara, C., Ozimek, N. E., Cheng, M., Bhargava, A., Memish-Beleva, Y., Lawney, B., Lavu, S., Swain, P. M., Apte, R. S., Sinclair, D. A., … Bhasin, S. (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of clinical endocrinology and metabolism, 108(8), 1968–1980. https://doi.org/10.1210/clinem/dgad027
  
• Yano, Y., Kim, H. C., Lee, H., Azahar, N., Ahmed, S., Kitaoka, K., Kaneko, H., Kawai, F., Mizuno, A., & Viera, A. J. (2022). Isolated Diastolic Hypertension and Risk of Cardiovascular Disease: Controversies in Hypertension - Pro Side of the Argument. Hypertension (Dallas, Tex. : 1979), 79(8), 1563–1570. https://doi.org/10.1161/HYPERTENSIONAHA.122.18459